Clinical trials: Estrogen, active
Endometriosis
Use of a New Diagnostic Tool in the Detection and Characterization of Endometriosis Lesions
Diagnostic wandering is one of the characteristics of endometriosis due to great anatomical and clinical variability but also due to poorly relevant diagnostic examinations.
- Trial name
- ENDO-TEP (NCT07053982)
- Testing
- Preoperative [18F]-FES PET/CT Imaging and Estrogen Receptor Expression Analysis in Endometriosis Surgery
- Where
- France
- Volunteers
- 20 people
- Sponsor
- University Hospital, Toulouse
PTSD and Trauma-related Symptoms, Cognitive Decline in Older Adults
Acute Effects of Estradiol Administration on Brain Function During Fear Learning
The goal of current study is to better understand how fear is processed in the brain and how these processes are influenced by cognition and hormones.
- Conditions
- PTSD and Trauma-related Symptoms, Cognitive Decline in Older Adults, Post Menopausal Women
- Trial name
- EstroFearGen (NCT07737613)
- Testing
- estradiol
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University of Arizona
Ductal Carcinoma in Situ of the Breast
Avoiding Surgery in Estrogen Receptor Positive Atypical Ductal Hyperplasia and In-situ Carcinoma Treated With Endocrine Treatment Trial
This study aims to evaluate the 5-year invasive ipsilateral breast cancer incidence rate in patients with hormone-receptor positive, HER-2 negative atypical ductal hyperplasia or in-situ carcimona who omitted surgery and received…
- Trial name
- ASAIN (NCT07245316)
- Testing
- Avoiding surgery
- Where
- South Korea
- Volunteers
- 340 people
- Sponsor
- Jeong Eon Lee
Breast Cancer, Ductal Carcinoma
Randomized Double-Blind Phase II Trial of Baby Exemestane Versus Baby Tamoxifen in Post-Menopausal Women at High Risk for Breast Cancer
The goal of this research study is to evaluate the efficacy and safety of low-dose exemestane versus low-dose tamoxifen in post-menopausal women at high risk for breast cancer.
- Conditions
- Breast Cancer, Ductal Carcinoma, Estrogen-receptor-positive Breast Cancer, Atypical Lobular Hyperplasia
- Trial name
- BabyTEARS (NCT07499999)
- Testing
- Exemestane, Tamoxifen
- Where
- 2 sites in United States
- Volunteers
- 140 people
- Sponsor
- Dana-Farber Cancer Institute
To Determine Whether Estrogen Influences the Effects of Training on Glycemic Control and Insulin Sensitivity
Does Estrogen Blunt the Effects of Exercise Training on Glycemic Control
Previous research has found that males and females respond differently to exercise training, particularly with respect to improvements in blood sugar control and immune system health.
- Trial name
- NCT07791394
- Testing
- EXERCISE TRAINING WITH OR WITHOUT MEDICATION
- Where
- Canada
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- University of Waterloo
Advanced Breast Cancer
A Phase Ib/II Study of QLC1401 Combined With CDK4/6 or mTOR Inhibitors in ER+/HER2- Advanced Breast Cancer
This study is an open-label, multicenter, Phase Ib/II clinical trial designed to evaluate the safety, tolerability, efficacy, and pharmacokinetic characteristics of QLC1401 tablets in combination with CDK4/6 inhibitors or mTOR…
- Trial name
- NCT07173556
- Testing
- QLC1401
- Volunteers
- 96 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Receptors, Estrogen, Genes, Erbb-2
A Study of H3B-6545 in Combination With Palbociclib in Women With Advanced or Metastatic Estrogen Receptor-Positive Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer
The primary objective of this study is to evaluate the safety and tolerability of H3B-6545 and palbociclib when administered in combination in order to determine the maximum tolerated dose (MTD) and/or the recommended Phase 2…
- Conditions
- Receptors, Estrogen, Genes, Erbb-2, Breast Neoplasms
- Trial name
- NCT04288089
- Testing
- Palbociclib (75, 100, 125 milligram [mg]), H3B-6545 (150, 300, 450 mg)
- Where
- 8 sites in United States, United Kingdom
- Volunteers
- 31 people
- Sponsor
- Eisai Inc.
Uterine Cancer
[18F]FES PET/.CT in Uterine Cancer
Women with known or suspected recurrent or metastatic uterine cancer may be eligible for this study. Patients may participate in this study if they are at least 18 years of age, most participants will be receiving care at the…
- Trial name
- NCT05916196
- Testing
- 18F-Fluoroestradiol
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Acne Vulgaris, Acne Vulgaris on the Face
Study of New Antiandrogenic Progestogen + Low-dose Estrogen for Moderate Acne Vulgaris
This Phase III randomized, double-blind, placebo-controlled, adaptive, multicenter study evaluates the efficacy and safety of a new concentration of the fixed-dose combination EF190 in women with moderate acne vulgaris over six…
- Trial name
- PANDORA (NCT06905210)
- Testing
- Experimental drug (Cyproterone Acetate 2 mg and Ethinyl Estradiol 0.02 mg)
- Where
- 18 sites in Brazil
- Volunteers
- 531 people
- Sponsor
- Eurofarma Laboratorios S.A.
Postmenopausal Symptoms, Cardiovascular Diseases
Estrogen Deficiency on Cardiovascular Risk
To explore how estrogen deficiency impacts the blood pressure (BP) and sympathetic nerve activity (SNA), and how it impacts the production of the key pro-inflammatory mediators such as Tumor necrosis factor α (TNF-α)…
- Trial name
- NCT06369363
- Testing
- Estradiol
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Milton S. Hershey Medical Center
Breast Cancer
Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)
The purpose of this study is to assess the efficacy and safety of pembrolizumab (MK-3475) versus placebo in combination with neoadjuvant (pre-surgery) chemotherapy and adjuvant (post-surgery) endocrine therapy in the treatment of…
- Trial name
- NCT03725059
- Testing
- Pembrolizumab (K), Paclitaxel (X), Doxorubicin (A)
- Where
- 244 sites in United States, Australia and 22 more
- Volunteers
- 1,240 people
- Sponsor
- Merck Sharp & Dohme LLC
Metastatic Breast Cancer
STUDY02001740;22SCH740: Estradiol For ER+ Advanced Breast Cancer (ESTHER)
Determine whether subjects harboring ESR1-mutant/amplified breast cancer have a higher rate of clinical benefit from 17b-estradiol therapy than subjects with ESR1-wild-type breast cancer
- Trial name
- ESTHER (NCT05716516)
- Testing
- Estradiol
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Body Composition, Muscle Function
GLP-1RA Effects on Lean Mass and Bone Health in Midlife Women
This study is designed with the interest to learn on the effects of estrogen levels and how it affects body compositions and muscle function in midlife women who are taking a GLP-1RA for weight loss.
- Conditions
- Body Composition, Muscle Function, GLP-1, Estrogen Level
- Trial name
- GLOW (NCT07422987)
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- University of Kansas Medical Center
Chronic Obstructive Lung Disease, Respiratory Ilness
InvEstigating oeStrogen Signalling and the Effect upoN the exTracelluar Matrix In pAtients With Obstructive Lung Disease
This study aims to understand the role of oestrogen in patients with asthma and Chronic Obstructive Pulmonary Disorder (COPD). Therefore, what is the effect of oestrogen in these participants compared to controls (those without…
- Conditions
- Chronic Obstructive Lung Disease, Respiratory Ilness, Estrogen Deficiency, Asthma
- Trial name
- ESSENTIAL (NCT06713512)
- Testing
- No intervention
- Where
- United Kingdom
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Guy's and St Thomas' NHS Foundation Trust
Uterine Sarcoma, Uterine Leiomyosarcoma
Ph 2 Elacestrant in ER Positive Uterine Sarcomas
This study is to evaluate the efficacy and safety of elacestrant, in participants with advanced estrogen receptor (ER)-positive uterine sarcomas.
- Conditions
- Uterine Sarcoma, Uterine Leiomyosarcoma, Endometrial Stromal Sarcoma, ESS
- Trial name
- NCT07467772
- Testing
- Elacestrant
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Dana-Farber Cancer Institute
HER2/Neu Positive, Recurrent Breast Carcinoma
Z-Endoxifen Hydrochloride in Treating Patients With Metastatic or Locally Recurrent Estrogen Receptor-Positive Breast Cancer
This phase I trial studies the side effects and the best dose of Z-endoxifen hydrochloride in treating patients with estrogen receptor-positive (ER+) breast cancer that has spread to other places in the body (metastatic) or has…
- Conditions
- HER2/Neu Positive, Recurrent Breast Carcinoma, Stage IIIC Breast Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7
- Trial name
- NCT01327781
- Testing
- Endoxifen Hydrochloride, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- 3 sites in United States
- Volunteers
- 62 people
- Sponsor
- National Cancer Institute (NCI)
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8
Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial
This phase III trial compares standard of care hormone therapy plus ribociclib to chemotherapy followed by hormone therapy plus ribociclib for the treatment of patients with high anatomic stage breast cancer with low risk of the…
- Conditions
- Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Estrogen Receptor-Positive Breast Carcinoma
- Trial name
- NCT07391774
- Testing
- Anastrozole, Biospecimen Collection, Bone Scan
- Where
- 258 sites in United States, Puerto Rico
- Volunteers
- 1,978 people
- Sponsor
- National Cancer Institute (NCI)
Estrogen Receptor-positive, Early Stage Endometrial Cancer
Phase II Study of CAmizestrant in Resectable Endometrial Adenocarcinoma
This is a window of opportunity study designed to provide short duration exposure to camizestrant prior to planned curative intent surgery, with the anticipated benefit of demonstrating target engagement and suppression of ER…
- Trial name
- CARA (NCT07840443)
- Testing
- Camizestrant
- Where
- 6 sites in Canada
- Volunteers
- 30 people
- Sponsor
- University Health Network, Toronto
Breast Neoplasms
A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
This study will include two groups of patients: Cohort 1 and Cohort 2. Cohort 1: will help researchers learn how a medicine called imlunestrant (LY3484356) affects a specific type of breast cancer.
- Trial name
- preEMBER (NCT07287098)
- Testing
- Imlunestrant, Goserelin, Tamoxifen 20 mg
- Where
- 90 sites in United States, Belgium and 5 more
- Volunteers
- 600 people
- Sponsor
- Eli Lilly and Company
Pelvic Organ Prolapse (POP)
Vaginal Estrogen for Improvement of Outcomes Following Pelvic Organ Prolapse Surgery
This open-label randomized control trial will study the use of vaginal estrogen in the first six weeks after pelvic organ prolapse (POP) repair surgery.
- Trial name
- VEPO (NCT07030426)
- Testing
- Vaginal Estrogen - Twice Weekly, Vaginal Estrogen - Daily
- Where
- 2 sites in Canada
- Volunteers
- 180 people
- Sponsor
- Sarah Wozney